EATON
5.7.2022 11:02:09 CEST | Business Wire | Press release
Intelligent power management company Eaton today announced its involvement in a pan-European research and innovation project to deliver the integrated technologies and business models needed to support mass deployment of electric vehicle charging infrastructure.
Supported by the European Union’s Horizon Europe Research and Innovation program, the €9.87M ($10.41M) project will span four years to March 2026, its scope covering the entire electric vehicle charging value chain. The FLOW project consortium, which includes 24 external partners and six leading universities across Europe, will be led by the Fundació Institut De Recerca En Energia De Catalunya .
Eaton’s role in the consortium will involve further developing electric vehicle charging technologies, as well as demonstrating electric vehicle charging solutions, based on experience advancing its Buildings as a Grid approach to uniting the power needs of buildings and electric vehicles with on-site renewable energy generation.
The research and innovation focus will extend across vehicle-to-grid (V2G) and vehicle-to-everything (V2X) capabilities that enable more system flexibility; DC-DC charging (direct current to direct current) that yields both power quality and control benefits; and further work on Eaton’s proprietary Buildings as a Grid Energy Management System that supports forecasting, optimization, and other essential services. To combine the various technologies into a complete solution, several Eaton business units will collaborate on the project—including the pan-European Eaton Research Labs team and the Eaton Center for Intelligent Power in Dublin, Ireland.
Stefan Costea, regional technology manager, Eaton Research Labs, said: “As electric vehicles grow in popularity across Europe, a comprehensive range of fully integrated charging technologies is urgently needed to support mass deployment and enable valuable new services. As a key partner in the FLOW project, we’re thrilled to be developing optimal solutions for electric vehicle charging, V2G, V2X, and energy management. We will demonstrate these technologies at three test labs—at the Eaton European Innovation Center in Prague, at University College Dublin , and at the Fundació Institut De Recerca En Energia De Catalunya, in Barcelona. Additionally, we will be supporting large scale technology demonstrations in Rome and Copenhagen with our energy management systems.”
For the demonstrations in Prague and Barcelona, Eaton will be collaborating closely with Heliox , a market leader in fast charging solutions. University College Dublin and nearby Maynooth University will work with Eaton in Ireland, while RWTH Aachen University , in Germany, will partner with Eaton in Prague on a techno-economic analysis of electric vehicle charging infrastructure use cases. In Rome and Copenhagen, Eaton will collaborate on energy management system interoperability with companies well-known for transmission and distribution: ENEL , Terna , and Areti, in addition to partners at Ricerca Sul Sistema Energetico and the Technical University of Denmark .
Tim Darkes, President, Corporate and Electrical, EMEA, Eaton, explained the context for Eaton’s involvement in the FLOW consortium, saying: “Our work on integrating charging infrastructure into buildings is supporting the rapid move to electric vehicles as part of the energy transition and we’re very proud to be investing heavily in the people, technologies, and programs to accelerate the global drive towards a low-carbon future.”
Jörgen von Bodenhausen, senior manager, Government Programs, Eaton, also added: “We continually seek out opportunities to combine our global scale and expertise with that of world-class industrial and academic partners, thus magnifying our own innovation efforts. From building-in energy management, to DC-DC charging, our work on the FLOW project will help pioneer new solutions to accelerate the commercialization and mass deployment of electric vehicle charging infrastructure and create whole new value propositions for both companies and customers.”
About Eaton
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.
Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com . Follow us on Twitter and LinkedIn .
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005048/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom